Thomas Björk - Search Results

Year	Number of Results
2003	2
2004	1
2005	1
2006	3
2007	3
2008	2
2010	2
2011	1
2012	1
2013	1
2014	1
2015	1
2024	0

1

Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study.

Vickers AJ, Cronin AM, Björk T, Manjer J, Nilsson PM, Dahlin A, Bjartell A, Scardino PT, Ulmert D, Lilja H. Vickers AJ, et al. Among authors: bjork t. BMJ. 2010 Sep 14;341:c4521. doi: 10.1136/bmj.c4521. BMJ. 2010. PMID: 20843935 Free PMC article.

2

Strategy for detection of prostate cancer based on relation between prostate specific antigen at age 40-55 and long term risk of metastasis: case-control study.

Vickers AJ, Ulmert D, Sjoberg DD, Bennette CJ, Björk T, Gerdtsson A, Manjer J, Nilsson PM, Dahlin A, Bjartell A, Scardino PT, Lilja H. Vickers AJ, et al. Among authors: bjork t. BMJ. 2013 Apr 15;346:f2023. doi: 10.1136/bmj.f2023. BMJ. 2013. PMID: 23596126 Free PMC article.

3

A novel automated platform for quantifying the extent of skeletal tumour involvement in prostate cancer patients using the Bone Scan Index.

Ulmert D, Kaboteh R, Fox JJ, Savage C, Evans MJ, Lilja H, Abrahamsson PA, Björk T, Gerdtsson A, Bjartell A, Gjertsson P, Höglund P, Lomsky M, Ohlsson M, Richter J, Sadik M, Morris MJ, Scher HI, Sjöstrand K, Yu A, Suurküla M, Edenbrandt L, Larson SM. Ulmert D, et al. Among authors: bjork t. Eur Urol. 2012 Jul;62(1):78-84. doi: 10.1016/j.eururo.2012.01.037. Epub 2012 Jan 27. Eur Urol. 2012. PMID: 22306323 Free PMC article.

4

Prostate-specific antigen at or before age 50 as a predictor of advanced prostate cancer diagnosed up to 25 years later: a case-control study.

Ulmert D, Cronin AM, Björk T, O'Brien MF, Scardino PT, Eastham JA, Becker C, Berglund G, Vickers AJ, Lilja H. Ulmert D, et al. Among authors: bjork t. BMC Med. 2008 Feb 15;6:6. doi: 10.1186/1741-7015-6-6. BMC Med. 2008. PMID: 18279502 Free PMC article.

5

Long-term prediction of prostate cancer: prostate-specific antigen (PSA) velocity is predictive but does not improve the predictive accuracy of a single PSA measurement 15 years or more before cancer diagnosis in a large, representative, unscreened population.

Ulmert D, Serio AM, O'Brien MF, Becker C, Eastham JA, Scardino PT, Björk T, Berglund G, Vickers AJ, Lilja H. Ulmert D, et al. Among authors: bjork t. J Clin Oncol. 2008 Feb 20;26(6):835-41. doi: 10.1200/JCO.2007.13.1490. J Clin Oncol. 2008. PMID: 18281654

6

Treatment costs for advanced prostate cancer using luteinizing hormone-releasing hormone agonists: a solid biodegradable leuprorelin implant versus other formulations.

Merseburger AS, Björk T, Whitehouse J, Meani D. Merseburger AS, et al. Among authors: bjork t. J Comp Eff Res. 2015 Sep;4(5):447-53. doi: 10.2217/cer.14.82. Epub 2014 Dec 18. J Comp Eff Res. 2015. PMID: 25521079 Free article.

7

Immunohistochemical detection of cysteine-rich secretory protein 3 in tissue and in serum from men with cancer or benign enlargement of the prostate gland.

Bjartell A, Johansson R, Björk T, Gadaleanu V, Lundwall A, Lilja H, Kjeldsen L, Udby L. Bjartell A, et al. Among authors: bjork t. Prostate. 2006 May 1;66(6):591-603. doi: 10.1002/pros.20342. Prostate. 2006. PMID: 16388501

8

Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44 to 50 years.

Lilja H, Ulmert D, Björk T, Becker C, Serio AM, Nilsson JA, Abrahamsson PA, Vickers AJ, Berglund G. Lilja H, et al. Among authors: bjork t. J Clin Oncol. 2007 Feb 1;25(4):431-6. doi: 10.1200/JCO.2006.06.9351. J Clin Oncol. 2007. PMID: 17264339

9

Tolerability, efficacy and pharmacokinetics of bicalutamide 300 mg, 450 mg or 600 mg as monotherapy for patients with locally advanced or metastatic prostate cancer, compared with castration.

Tyrrell CJ, Iversen P, Tammela T, Anderson J, Björk T, Kaisary AV, Morris T. Tyrrell CJ, et al. Among authors: bjork t. BJU Int. 2006 Sep;98(3):563-72. doi: 10.1111/j.1464-410X.2006.06275.x. Epub 2006 Jun 8. BJU Int. 2006. PMID: 16771791 Clinical Trial.

10

[Prostate-specific antigen--the most important cancer marker. Diagnostics and follow up of prostatic cancer have changed].

Bratt O, Björk T. Bratt O, et al. Among authors: bjork t. Lakartidningen. 2007 Nov 14-20;104(46):3460-4. Lakartidningen. 2007. PMID: 18072615 Review. Swedish. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

16 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

16 results

Results by year